ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49165
-0.03%
Bitcoin
66,899.69
-0.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV
  6. Psybio Therapeutics Corp (PSYB)

  7. Psybio Therapeutics Corp (PSYB) News

PSYB

Psybio Therapeutics (PSYB)

Psybio Therapeutics Corp
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:PSYB
DateTimeSourceHeadlineSymbolCompany
07/12/202316:25PR Newswire (Canada)TSX Venture Exchange Stock Maintenance BulletinsTSXV:PSYBPsybio Therapeutics Corp
07/12/202300:32PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PSYBTSXV:PSYBPsybio Therapeutics Corp
07/12/202300:30PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - PSYBTSXV:PSYBPsybio Therapeutics Corp
27/11/202323:53PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PSYBTSXV:PSYBPsybio Therapeutics Corp
27/11/202323:51PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - PSYBTSXV:PSYBPsybio Therapeutics Corp
09/12/202200:01PR Newswire (Canada)PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMTTSXV:PSYBPsybio Therapeutics Corp
07/12/202200:09PR Newswire (Canada)PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
01/12/202223:30PR Newswire (Canada)PsyBio Therapeutics Announces Non-Brokered Private Placement FinancingTSXV:PSYBPsybio Therapeutics Corp
29/11/202223:20PR Newswire (Canada)PsyBio Therapeutics Reports Third Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
11/10/202222:30PR Newswire (Canada)PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical TrialTSXV:PSYBPsybio Therapeutics Corp
19/09/202221:30PR Newswire (Canada)PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application AcceptedTSXV:PSYBPsybio Therapeutics Corp
07/09/202221:30PR Newswire (Canada)PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022TSXV:PSYBPsybio Therapeutics Corp
29/08/202221:30PR Newswire (Canada)PsyBio Therapeutics Reports Second Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
11/08/202221:30PR Newswire (Canada)PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent ApplicationTSXV:PSYBPsybio Therapeutics Corp
08/08/202221:30PR Newswire (Canada)PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent ApplicationsTSXV:PSYBPsybio Therapeutics Corp
28/06/202207:05PR Newswire (Canada)PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of ShareholdersTSXV:PSYBPsybio Therapeutics Corp
02/06/202221:30PR Newswire (Canada)PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive CompoundsTSXV:PSYBPsybio Therapeutics Corp
30/05/202221:25PR Newswire (Canada)PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development MilestonesTSXV:PSYBPsybio Therapeutics Corp
16/05/202221:30PR Newswire (Canada)PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted CompoundTSXV:PSYBPsybio Therapeutics Corp
06/05/202221:30PR Newswire (Canada)PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio DevelopmentTSXV:PSYBPsybio Therapeutics Corp
27/04/202221:30PR Newswire (Canada)PsyBio Therapeutics Begins Filing Global Provisional Patent Conversion Applications to Further Strengthen Biosynthetic Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
19/04/202221:30PR Newswire (Canada)PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022TSXV:PSYBPsybio Therapeutics Corp
13/04/202221:30PR Newswire (Canada)PsyBio Therapeutics Initiates Clinical Trial Site Selection ProcessTSXV:PSYBPsybio Therapeutics Corp
23/03/202222:30PR Newswire (Canada)PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022TSXV:PSYBPsybio Therapeutics Corp
15/03/202222:30PR Newswire (Canada)PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment StrategyTSXV:PSYBPsybio Therapeutics Corp
03/03/202211:24PR Newswire (Canada)PsyBio Therapeutics Reports Annual 2021 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
03/02/202200:34PR Newswire (Canada)PsyBio Therapeutics to Participate in Citi's Psychedelic Drug Video Call SeriesTSXV:PSYBPsybio Therapeutics Corp
10/01/202222:30PR Newswire (Canada)PsyBio Therapeutics to Present at the H.C. Wainwright Bioconnect ConferenceTSXV:PSYBPsybio Therapeutics Corp
07/12/202123:30PR Newswire (Canada)PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug AdministrationTSXV:PSYBPsybio Therapeutics Corp
02/12/202123:30PR Newswire (Canada)PsyBio Therapeutics Sponsors 16 Collaborative Research Abstract Presentations at Two Scientific ConferencesTSXV:PSYBPsybio Therapeutics Corp
 Showing the most relevant articles for your search:TSXV:PSYB

Your Recent History

NASDAQI
SX151010GI
OMX Stockholm Telecommun...
BIT
F00SPX
Vontobel Financial Produ...
USOTC
FCLOF
FirstWave Cloud Technology (PK)
CRTO
LDOBTC
Lido DAO Token
LSE
MRNC
BIT
UR9ZPF
UniCredit Bank
GATE
REIUSDT
REI Network
BIT
F15411
Vontobel Financial Produ...
BIT
FAEU
Invesco US High Yield Fa...
LSE
BZL
USOTC
FKKFF
Fukuoka Financial (PK)
BIT
S28295
Societe Generale Effekten
BOV
VALER675
VALER675 Ex:60,99
COIN
GOFGBP
Golff.finance
GATE
UPIUSDT
Pawtocol Network UPI Token
BIT
F33719
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved